Bone and Mineral Diagnostic Testing Market Report 2025

The bone and mineral diagnostic testing market size has grown steadily in recent years. It will grow from $1.09 billion in 2024 to $1.14 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to aging population demands, prevalence of osteoporosis, awareness and education initiatives, clinical need for monitoring, fracture risk assessment.

The bone and mineral diagnostic testing market size is expected to see strong growth in the next few years. It will grow to $1.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in diagnostic technologies, increasing incidence of metabolic bone diseases, growing focus on preventive healthcare, integration with personalized medicine approaches. Major trends in the forecast period include integration of biochemical markers, telemedicine and remote monitoring, expansion of home-based testing kits, collaborations for research and innovation, emphasis on comprehensive diagnostic panels.

An increase in the prevalence of bone-related diseases is expected to drive the growth of the bone and mineral diagnostic testing market in the future. Bone-related diseases are conditions that affect the strength or flexibility of bones, making them more susceptible to fractures, and can lead to symptoms such as bone pain, difficulty moving, and a higher risk of fractures. Bone and mineral diagnostic tests, including bone density tests, can help prevent bone diseases by detecting low bone density before osteoporosis develops, predicting the risk of future fractures, and monitoring the effectiveness of ongoing osteoporosis treatment. The rising incidence of bone-related diseases, combined with increasing awareness and technological advancements, is anticipated to fuel the growth of the bone and mineral diagnostic testing market. For example, in May 2022, the National Center for Biotechnology Information (NCBI), a US-based government organization, reported that the primary complication of osteoporosis is fractures, with projections indicating a 310% increase in global hip fractures among men and a 240% increase among women by 2050. Therefore, the rising incidence of bone-related diseases is set to drive the bone and mineral diagnostic testing market.

The increase in healthcare expenditure is expected to fuel the growth of the bone and mineral diagnostic testing market. Elevated healthcare spending facilitates broader access to advanced diagnostic technologies, including bone density assessments and mineral tests. This financial investment also supports research, development, and technological innovation in diagnostic methods. For instance, Statistics Poland reported a healthcare expenditure of PLN 205.6 billion ($50.99 billion) in 2022, representing 6.7% of GDP and an increase of PLN 36.1 billion ($8.95 billion) from 2021. This heightened expenditure contributes significantly to the growth of bone and mineral diagnostic testing.

Technological advancements emerge as a significant trend driving the bone and mineral diagnostic testing market. Companies in this sector are leveraging new technologies to maintain their market standing. For example, GE HealthCare Technologies Inc. developed an innovative MRI technique employing novel pulse sequences such as zero echo time (ZTE) to visualize tendons, ligaments, calcium deposits, and cortical bone structures. This MRI advancement offers CT-such as image contrast in 3D isotropic resolution without exposing patients to ionizing radiation, proving especially useful for obtaining morphological information in various anatomical structures.

Leading companies in the bone and mineral diagnostic testing market prioritize innovative solutions such as Vitamin D tests to solidify their market presence. These tests gauge the level of vitamin D in the blood, a crucial nutrient for bone health and immune system regulation. Hurdle, a brand under Chronomics Inc., introduced their Vitamin D Test in February 2023. This test measures 25-hydroxyvitamin D levels, essential for calcium regulation and overall health, available through providers such as Quest Diagnostics via in-person sampling or at-home test kits.

In May 2022, Quidel Corporation, a prominent US-based developer of diagnostic healthcare devices, merged with Ortho Clinical Diagnostics Holdings plc in a deal valued at $6 billion. This strategic union with Ortho is poised to fortify Quidel's standing as a leader in the diagnostics industry, consolidating a diverse range of innovative and complementary products, solutions, and services aimed at enhancing the health and overall well-being of patients on a global scale. Ortho Clinical Diagnostics, also based in the US, specializes in in vitro medical diagnostics, demonstrating a commitment to improving and transforming lives through pioneering laboratory testing and cutting-edge blood-typing technologies.

Major companies operating in the bone and mineral diagnostic testing market include Abbott Laboratories, bioMérieux SA, DiaSorin S.p.A., QuidelOrtho Corporation, Siemens Healthineers AG, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc., Hologic Inc., Beammed Ltd., Swissray International Inc., Osteosys Co. Ltd., Diagnostic Medical System SA, Medonica Co. Ltd., Epitope Diagnostics Inc., Alere Inc., Beckman Coulter Inc., Bio Rad Laboratories Inc., Calbiotech Inc., Roche Diagnostics India Pvt. Ltd., Ortho-Clinical Diagnostics, Enzo Life Sciences lnc., Medtronic plc, Thermo Fisher Scientific lnc., Sysmex Corporation, EKF Diagnostics, Bruker Corporation, Esaote SpA, Hitachi Ltd., Koninklijke Philips N.V., Mindray Medical International Limited, PerkinElmer Inc., Shimadzu Corporation, Toshiba Medical Systems Corporation, Waters Corporation, Danaher Corporation, Merck KGaA.

North America was the largest region in the bone and mineral diagnostic testing market in 2024. The regions covered in the bone and mineral diagnostic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bone and mineral diagnostic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A bone and mineral diagnostic test is a medical procedure designed to measure the levels of calcium and other minerals present in a specific bone segment. This test serves multiple purposes including the detection of bone loss and osteoporosis, monitoring the effectiveness of osteoporosis treatments, and evaluating the risk of fractures.

The primary components of bone and mineral diagnostic testing encompass assays or consumables and instrumentation. An assay refers to a laboratory procedure utilized to analyze the presence, quantity, or functional activity of a specific element in either a qualitative or quantitative manner. This method finds applications across diverse fields such as medicine, mining, pharmacy, and various branches of biology. Within bone and mineral diagnostic testing, assays such as enzyme-linked immunosorbent assay (ELISA), clinical laboratory improvement amendments (CLIA), among others, are utilized for assessments related to vitamin D levels and bone metabolism. These tests contribute significantly to the evaluation and understanding of bone health and mineral balance in the body.

The bone and mineral diagnostic testing market research report is one of a series of new reports that provides bone and mineral diagnostic testing market statistics, including bone and mineral diagnostic testing industry global market size, regional shares, competitors with an bone and mineral diagnostic testing market share, detailed bone and mineral diagnostic testing market segments, market trends and opportunities, and any further data you may need to thrive in the bone and mineral diagnostic testing industry. This bone and mineral diagnostic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bone and mineral diagnostic testing market includes revenues earned by entities by testing services such as bone mineral density (BMD) tests (bone densitometry) and bone scans (skeletal scintigraphy). The market value includes the value of related goods sold by the service provider or included within the service offering. The bone and mineral diagnostic testing market also includes sales of computed tomography scans (CT scans), magnetic resonance imaging (MRI), radionuclide bone scans, and bone biopsies, which are used in providing bone and mineral diagnostic testing services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.